The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis
Bonde, J.; Dahl, R.; Edelstein, R.; Kok-Jensen, A.; Lazer, L.; Punakivi, L.; Seppala, A.; Soes-Petersen, U.; Viskum, K.
European Journal of Respiratory Diseases 69(4): 235-241
1986
ISSN/ISBN: 0106-4339 PMID: 3545882 Document Number: 267811
The effect of Biostim (RU 41.740), a new non-specific immune modulator, in reducing the number of acute exacerbations in patients with chronic bronchitis, was examined. One hundred and ninety-eight patients with chronic bronchitis stages 2 and 3 entered the study, which was conducted as a multicenter, double-blind, parallel three-group, placebo-controlled trial. The patients were randomised to placebo, Biostim 2 or 8 mg per day, and received treatment for 1 week every other week for 3 successive months during the winter 1983. A significant (p = 0.005) reduction in the number of acute exacerbations was observed in the patients treated with Biostim 2 mg/day, whereas no effect was observed in the placebo or 8 mg/day group. No serious side-effects were encountered.